

Drug	Schedule	Drug	Schedule
Etorphine HCl (9059)	I	Hydromorphone (9150)	II
Codeine methylbromide (9070)	I	Diphenoxylate (9170)	II
Dihydromorphone (9145)	I	Benzoylcegonine (9180)	II
Difenoxin (9168)	I	Ethylmorphine (9190)	II
Heroin (9200)	I	Hydrocodone (9193)	II
Hydromorphinol (9301)	I	Levomethorphan (9210)	II
Methyldesorphine (9302)	I	Levorphanol (9220)	II
Methyldihydromorphone (9304)	I	Isomethadone (9226)	II
Morphine methylbromide (9305)	I	Meperidine (9230)	II
Morphine methylsulfonate (9306)	I	Meperidine intermediate-B (9233)	II
Morphine-N-oxide (9307)	I	Metazocine (9240)	II
Myrophine (9308)	I	Methadone (9250)	II
Nicocodeine (9309)	I	Methadone intermediate (9254)	II
Nicomorphine (9312)	I	Metopon (9260)	II
Normorphine (9313)	I	Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Pholcodine (9314)	I	Morphine (9300)	II
Acetorphine (9319)	I	Thebaine (9333)	II
Acetylmethadol (9601)	I	Dihydroetorphine (9334)	II
Allylprodine (9602)	I	Levo-alphaacetylmethadol (9648)	II
Alphaacetylmethadol except levo-alphaacetyl-methadol (9603)	I	Oxymorphone (9652)	II
Alphamethadol (9605)	I	Noroxymorphone (9668)	II
Dioxaphetyl butyrate (9621)	I	Phenazocine (9715)	II
Dipipanone (9622)	I	Piminodine (9730)	II
Ethylmethylthiambutene (9623)	I	Racemethorphan (9732)	II
Etonitazene (9624)	I	Racemorphan (9733)	II
Etoxidine (9625)	I	Alfentanil (9737)	II
Furethidine (9626)	I	Remifentanil (9739)	II
Hydroxypethidine (9627)	I	Sufentanil (9740)	II
Ketobemidone (9628)	I	Carfentanil (9743)	II
Levomoramide (9629)	I	Tapentadol (9780)	II
Levophenacymorphan (9631)	I	Bezitramide (9800)	II
Morpheridine (9632)	I	Fentanyl (9801)	II
Noracymethadol (9633)	I		
Norlevorphanol (9634)	I		
Normethadone (9635)	I		
Norpipanone (9636)	I		
Phenadoxone (9637)	I		
Phenampramide (9638)	I		
Phenoperidine (9641)	I		
Piritramide (9642)	I		
Proheptazine (9643)	I		
Propenidine (9644)	I		
Racemoramide (9645)	I		
Trimeperidine (9646)	I		
Phenomorphane (9647)	I		
Levo-alphaacetylmethadol (9648)	I		
Propiram (9649)	I		
Tilidine (9750)	I		
Para-Fluorofentanyl (9812)	I		
3-Methylfentanyl (9813)	I		
Acetyl-alpha-methylfentanyl (9815)	I		
Amphetamine (1100)	II		
Methamphetamine (1105)	II		
Lisdexamfetamine (1205)	II		
Phenmetrazine (1631)	II		
Methylphenidate (1724)	II		
Amobarbital (2125)	II		
Pentobarbital (2270)	II		
Secobarbital (2315)	II		
Glutethimide (2550)	II		
Nabilone (7379)	II		
1-Phenylcyclohexylamine (7460)	II		
Phencyclidine (7471)	II		
4-Anilino-N-phenethyl-4-piperidine (8333)	II		
Phenylacetone (8501)	II		
Alphaprodine (9010)	II		
Anileridine (9020)	II		
Cocaine (9041)	II		
Codeine (9050)	II		
Dihydrocodeine (9120)	II		
Oxycodone (9143)	II		

Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: April 2, 2012.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-8763 Filed 4-11-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice Of Registration; Cerilliant Corporation**

By Notice dated January 6, 2012, and published in the **Federal Register** on January 17, 2012, 77 FR 2321, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

Drug	Schedule
Cathinone (1235)	I
Methcathinone (1237)	I
N-Ethylamphetamine (1475)	I
N,N-Dimethylamphetamine (1480)	I
Fenethylamine (1503)	I
Gamma Hydroxybutyric Acid (2010)	I
Alpha-ethyltryptamine (7249)	I
Ibogaine (7260)	I
Lysergic acid diethylamide (7315) Drug Schedule.	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)	I
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I
Mescaline (7381)	I
3,4,5-Trimethoxyamphetamine (7390)	I
4-Bromo-2,5-dimethoxyamphetamine (7391)	I
4-Bromo-2,5-dimethoxyphenethylamine (7392)	I
4-Methyl-2,5-dimethoxyamphetamine (7395)	I
2,5-Dimethoxyamphetamine (7396)	I
3,4-Methylenedioxyamphetamine (7400)	I
3,4-Methylenedioxy-N-ethylamphetamine (7404)	I
3,4-Methylenedioxymethamphetamine (7405)	I
4-Methoxyamphetamine (7411)	I
5-Methoxy-N-N-dimethyltryptamine (7431)	I

The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration, and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, **Federal Register** Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than May 14, 2012.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, 40 FR 43745-46, all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement

Drug	Schedule
Alpha-methyltryptamine (7432) ....	I
Diethyltryptamine (7434) .....	I
Dimethyltryptamine (7435) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
5-Methoxy-N,N-diisopropyltryptamine (7439).	I
N-Benzylpiperazine (7493) .....	I
Etorphine (except HCl) (9056) ....	I
Heroin (9200) .....	I
Morphine-N-oxide (9307) .....	I
Normorphine (9313) .....	I
Pholcodine (9314) .....	I
Dextromoramide (9613) .....	I
Dipipanone (9622) .....	I
Racemoramide (9645) .....	I
Drug Schedule.	
Trimeperidine (9646) .....	I
Tilidine (9750) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Methylphenidate (1724) .....	II
Amobarbital (2125) .....	II
Pentobarbital (2270) .....	II
Secobarbital (2315) .....	II
Phencyclidine (7471) .....	II
Phenylacetone (8501) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Benzoyllecgonine (9180) .....	II
Ethylmorphine (9190) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Dextropropoxyphene, bulk (non-dosage forms) (9273).	II
Morphine (9300) .....	II
Oripavine (9330) .....	II
Thebaine (9333) .....	II
Levo-alphaacetylmethadol (9648) ..	II
Oxymorphone (9652) .....	II
Poppy Straw Concentrate (9670) ..	II
Fentanyl (9801) .....	II

The company plans to import small quantities of the listed controlled substances for the manufacture of analytical reference standards.

In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No other activity for this drug code is authorized for this registration.

Comments and requests for hearings on applications to import narcotic raw material are not appropriate, 72 FR 3417 (2007). Regarding all other basic classes of controlled substances, no comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Cerilliant Corporation to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. DEA has investigated

Cerilliant Corporation to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: April 2, 2012.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012-8766 Filed 4-11-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Office of Justice Programs**

[OJP (OJJDP) Docket No. 1586]

**Hearing of the Attorney General's National Task Force on Children Exposed to Violence**

**AGENCY:** Office of Justice Programs (OJP), Justice.

**ACTION:** Notice of hearing.

**SUMMARY:** This is an announcement of the fourth hearing of the Attorney General's National Task Force on Children Exposed to Violence (the "task force"). The task force is chartered to provide OJP, a component of the Department of Justice, with valuable advice in the areas of children exposed to violence for the purpose of addressing the epidemic levels of exposure to violence faced by our nation's children. Based on the testimony at four public hearings; comprehensive research; and extensive input from experts, advocates, and impacted families and communities nationwide, the task force will issue a final report to the Attorney General presenting its findings and comprehensive policy recommendations in the fall of 2012.

**DATES:** The hearing will take place on Monday, April 23; Tuesday, April 24; and Wednesday, April 25, 2012.

**ADDRESSES:** The hearing will take place at Wayne State University in the Bernath Auditorium on the first floor of the David Adamany Undergraduate Library, 5155 Gullen Mall, Detroit, MI 48202.

**FOR FURTHER INFORMATION CONTACT:** Will Bronson, Designated Federal Official (DFO), Deputy Associate Administrator, Child Protection Division, Office of Juvenile Justice & Delinquency Prevention, Office of Justice Programs, 810 7th Street NW., Washington, DC 20531. Phone: (202) 305-2427 [note: this is not a toll-free number]; email: [willie.bronson@usdoj.gov](mailto:willie.bronson@usdoj.gov).

**SUPPLEMENTARY INFORMATION:** This hearing is being convened to brief the task force members about the issue of children's exposure to violence. The final agenda is subject to adjustment, but it is anticipated that on April 23, there will be an evening session devoted to public testimony. On April 24, there will be a morning and afternoon session, with a break for lunch. The morning session will likely include welcoming remarks, introductions, and panel presentations from invited guests on the impact of children's exposure to violence. The afternoon session will continue with panel presentations from invited guests. April 25 will likely be devoted to a working meeting of task force members.

This meeting is open to the public. Members of the public who wish to attend this meeting must provide photo identification upon entering the hearing facility. Access to the meeting will not be allowed without identification. In order to best prepare for attendees, members of the public who wish to attend this meeting may register with Will Bronson at [defendingchildhoodtaskforce@nccdcrc.org](mailto:defendingchildhoodtaskforce@nccdcrc.org) in advance of the meeting. Registrations will be accepted on a space available basis. Prior registration is not required to attend this event, but is required for those who wish to provide testimony.

Time for public testimony is scheduled from 5 p.m. to 7 p.m. Eastern on April 23. Public testimony must be provided in person and will be limited to three (3) minutes per witness. Members of the public who wish to provide testimony must register with Will Bronson at [defendingchildhoodtaskforce@nccdcrc.org](mailto:defendingchildhoodtaskforce@nccdcrc.org) by April 20. Please bring photo identification and allow extra time prior to the meeting. Persons interested in communicating with the task force should submit their written comments to the DFO at [defendingchildhoodtaskforce@nccdcrc.org](mailto:defendingchildhoodtaskforce@nccdcrc.org), as the time available will not allow the public to directly address the task force (except as provided above) at the meeting.

Anyone requiring special accommodations should notify Mr.